Nippon Chemiphar : Chemiphar announced third quarter business summary FY2020. (pdf, 274KB)
January 29, 2021 at 02:18 am EST
Share
（TSE 4539）
FY2020 Third Quarter Business Summary
(Year Ending March 31, 2021)
Sales, Income
(¥mn)
FY2019
FY2020
3Q
Distrib. Full Year
3Q
Distrib.
YOY
Full Year
Progress
Amount
(%)
Amount
Amount
(%)
(%)
(Forecast1)
Rate (%)
Net sales
24,266
100.0
31,756
23,612
100.0
(2.7)
31,000
76.2
Pharmaceuticals
23,678
97.6
30,632
22,972
97.3
(3.0)
―
―
Others
588
2.4
1,123
640
2.7
8.8
―
―
Cost of sales
14,416
59.4
19,200
14,855
62.9
3.0
―
―
SG&A expenses
9,222
38.0
12,190
8,296
35.1
(10.0)
―
―
R&D expenses
1,625
6.7
2,173
1,565
6.6
(3.7)
2,200
71.2
Operating income
627
2.6
364
460
1.9
(26.7)
200
230.0
Income before income taxes
and minority interests
989
4.1
732
436
1.8
(55.8)
―
―
Net income attributable to
owners of the prent
667
2.8
436
335
1.4
(49.8)
50
670.8
Note:
1. Issued on October 30, 2020.
1
Pharmaceutical Sales
Generics, Proprietary Products and New Drugs
(¥mn)
FY2019
FY2020
3Q
Distrib.
Full Year
3Q
Distrib.
YOY
Full Year
Progress
Amount
(%)
Amount
Amount
(%)
(%)
(Forecast1)
Rate (%)
Total
21,562
100.0
27,792
20,733
100.0
(3.8)
27,040
76.7
Generics
20,502
95.1
26,429
19,379
93.5
(5.5)
25,190
76.9
To medical institutions
19,811
25,446
18,636
(5.9)
24,200
77.0
To other makers2
690
983
743
7.6
990
75.1
Amlodipine
2,073
2,646
1,884
(9.1)
2,370
79.5
Lansoprazole
983
1,197
754
(23.3)
990
76.2
Donepezil
810
1,005
649
(19.8)
850
76.4
Rabeprazole
995
1,346
1,087
9.2
1,360
79.9
Limaprost Alfadex
752
947
587
(22.0)
740
79.4
Others
14,886
18,303
14,416
(3.2)
18,880
76.4
Proprietary products and new drugs
1,060
4.9
1,362
1,354
6.5
27.7
1,850
73.2
Uralyt
657
842
573
(12.8)
740
77.5
Others
402
520
780
93.9
1,110
70.3
Chemiphar, ODM Generics
(¥mn)
FY2019
FY2020
3Q
Distrib.
Full Year
3Q
Distrib.
YOY
Full Year
Progress
Amount
(%)
Amount
Amount
(%)
(%)
(Forecast1)
Rate (%)
Total
21,203
100.0
27,322
20,273
100.0
(4.4)
26,290
77.1
Generics
20,502
96.7
26,425
19,379
95.6
(5.5)
25,190
76.9
Generics (ODM)
701
3.3
896
894
4.4
27.5
1,100
81.3
Note:
Issued on October 30, 2020.
Includes exports
2
Sales Distribution
By Launch Year
(¥mn)
FY2019
FY2020
3Q
Distrib.
3Q
Distrib.
YOY
Amount
(%)
Amount
(%)
(%)
FY2013 and before
16,018
78.1
14,008
72.3
(12.5)
FY2014
1,304
6.4
1,351
7.0
3.6
FY2015
854
4.2
802
4.1
(6.1)
FY2016
458
2.2
396
2.0
(13.4)
FY2017
1,065
5.2
1,094
5.6
2.7
FY2018
727
3.5
672
3.5
(7.6)
FY2019
73
0.4
94
0.5
27.8
FY2020
―
―
958
4.9
―
Total
20,502
100.0
19,379
100.0
(5.5)
By Main Therapeutic Categories
(%)
FY2019
FY2020
3Q
3Q
Distrib.
Distrib.
Cardiovascular and respiratory drugs
32.6
30.2
Digestive organ drugs
16.3
15.6
Agents affecting metabolism
15.3
15.6
Drugs for nervous system, sensory organs
9.3
11.9
Antibiotics and chemotherapeutic drugs
5.4
6.5
Antineoplastic agents
3.4
3.0
Others
17.7
17.2
3
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Nippon Chemiphar Co. Ltd. published this content on 29 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 January 2021 07:17:00 UTC.
NIPPON CHEMIPHAR CO., LTD. is a Japan-based company centered on ethical pharmaceutical products and mainly engaged in the pharmaceutical, health and beauty related businesses. The Companyâs Pharmaceutical segment is engaged in the manufacture and sale of ethical pharmaceutical products. Other businesses include entrusted safety testing, healthcare and real estate leasing business. The Company mainly operates in Japan and Vietnam.
NIPPON CHEMIPHAR CO., LTD. 
